Real-World Experience of Bevacizumab as First-Line Treatment for Ovarian Cancer: The GINECO ENCOURAGE Cohort of 468 French Patients

• Main Authors: Dominique Berton (Author), Anne Floquet (Author), Willy Lescaut (Author), Gabriel Baron (Author), Marie-Christine Kaminsky (Author), Philippe Toussaint (Author), Rémy Largillier (Author), Aude-Marie Savoye (Author), Jérôme Alexandre (Author), Catherine Delbaldo (Author), Emmanuelle Malaurie (Author), Hugues Barletta (Author), Claire Bosacki (Author), Claire Garnier-Tixidre (Author), Philippe Follana (Author), Hortense Laharie-Mineur (Author), Charles Briac Levache (Author), Bruno Valenza (Author), Agnès Dechartres (Author), Delphine Mollon-Grange (Author), Frédéric Selle (Author)
• Format: Book
• Published: Frontiers Media S.A., 2021-09-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Introduction: Bevacizumab-containing therapy is considered a standard-of-care front-line option for stage IIIB-IV ovarian cancer based on results of randomized phase 3 trials. The multicenter non-interventional ENCOURAGE prospective cohort study assessed treatment administration and outcomes in the...